계명대학교 의학도서관 Repository

Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry

Metadata Downloads
Author(s)
Hyoung-Seob ParkHyuck-Jun YoonHyungseop KimSeongwook HanSeung-Ho HurYoon-Nyun KimKwon-Bae KimJae-Kean RyuDeug Young NahChang-Wook NamHan Joon BaeYun-Kyeong Cho
Keimyung Author(s)
Kim, Kwon BaeKim, Yoon NyunCho, Yun KyeongPark, Hyoung SeobYoon, Hyuck JunKim, Hyung SeopHan, Seong WookHur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
The Korean Journal of Internal Medicine
Issued Date
2020
Volume
35
Issue
2
Keyword
DyslipidemiasCholesterolHydroxymethylglutaryl-CoA reductase inhibitors
Abstract
Background/Aims:
To date, prospective data are limited on efficacy and safety profiles of statin therapy in Korean hypercholesterolemic patients. Hence, the aim of this study was to evaluate the practice patterns of statin therapy and its efficacy and safety through the prospective Daegu and Gyeongbuk statin registry.

Methods:
Statin naïve patients who were prescribed statins according to the criteria of Korean Guidelines for Management of Dyslipidemia were enrolled. Clinical and laboratory evaluations were performed at baseline and at week 8, where the efficacy was assessed with the same guidelines.

Results:
Of 908 patients, atorvastatin and rosuvastatin were most frequently prescribed statins (63.1% and 29.3%, respectively). High intensity statins (atorvastatin 40 mg or rosuvastatin 20 mg) were prescribed in 24.7% of all patients and in 79.5% of high and very high risk groups. The total and low density lipoprotein (LDL) cholesterol levels decreased from 203.7 ± 43.0 to 140.6 ± 28.6 mg/dL and 134.4 ± 35.7 to 79.5 ± 21.3 mg/dL, respectively. The achievement rate of the LDL target goal was 98.6% in low risk, 95.0% in moderate risk, 88.1% in high risk, and 42.1% in very high risk patients (59.7% in overall). There was no significant difference in the efficacy between atorvastatin and rosuvastatin. Adverse events were observed in 12.0% of patients and led to 1.4% of treatment cessation.

Conclusions:
The efficacy of the usual starting dose of statins in daily practice was relatively insufficient for Korean hypercholesterolemic patients with high or very high risks. Short-term adverse events of statin therapy were not common in Korean patients with a low discontinuation rate.
Alternative Title
Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry
Keimyung Author(s)(Kor)
조윤경
박형섭
윤혁준
김형섭
한성욱
허승호
김윤년
김권배
남창욱
Publisher
School of Medicine (의과대학)
Citation
Hyoung-Seob Park et al. (2020). Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry. The Korean Journal of Internal Medicine, 35(2), 342–350. doi: 10.3904/kjim.2018.272
Type
Article
ISSN
2005-6648
Source
http://kjim.org/journal/view.php?doi=10.3904/kjim.2018.272
DOI
10.3904/kjim.2018.272
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/42694
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.